China-U.S. Listing Agreement Clears Path for Chinese Firms to Stay Listed in the U.S.
China and the United States are nearing an agreement that would allow Chinese firms to...
Zai Lab
Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 2022 financial report,...
Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...
Zai Lab’s Repotrectinib Earns Two Breakthrough Therapy Designations in China for ROS1+ NSCLC
China-based biopharma Zai Lab Ltd (NASDAQ: ZLAB) announced receiving two breakthrough therapy designations (BTDs) from...
Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients
Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...